Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)

Journal of Clinical Oncology

Volumn 31, Issue 35, 2013, Pages 4424-4430

  Amadori, Sergio ^a   Suciu, Stefan ⁱ   Stasi, Roberto ^m   Salih, Helmut R ⁿ   Selleslag, Dominik ^k   Muus, Petra ^p   De Fabritiis, Paolo ^b   Venditti, Adriano ^a   Ho, Anthony D ^o   Lübbert, Michael ^o   Thomas, Xavier ^r   Latagliata, Roberto ^c   Halkes, Constantijn J M ^q   Falzetti, Franca ^f   Magro, Domenico ^g   Guimaraes, José E ^q   Berneman, Zwi ^l   Specchia, Giorgina ^h   Karrasch, Matthias ^j   Fazi, Paola ^d   Vignetti, Marco ^e   Willemze, Roel ^p   De Witte, Theo ^r   Marie, Jean Pierre ^s   more..

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b St Eugenio Hospital   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Gruppo Malattie Ematologiche dell'Adulto Data Center   (Italy)

^e University Hospital   (Italy)

^f PUGLIESE CIACCIO HOSPITAL   (Italy)

^g POLICLINICO   (Italy)

^h EORTC DATA CENTER   (Belgium)

ⁱ General Hospital St Jan   (Belgium)

^j ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^k ST GEORGE S HOSPITAL   (United Kingdom)

^l UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^m UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^p LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^q EDOUARD HERRIOT HOSPITAL   (France)

^r HÔPITAL SAINT ANTOINE   (France)

^s Centro Hospitalar Universitario do Porto   (Portugal)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GERIATRIC PATIENT; HEART DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA REMISSION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH DISEASE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ACUTE DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; LEUKEMIA, MYELOID; LIVER; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; REMISSION; SURVIVAL; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METHODOLOGY; MYELOID LEUKEMIA;

ACUTE DISEASE; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA, MYELOID; LIVER; MALE; MIDDLE AGED; MITOXANTRONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84894352589     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.0771     Document Type: Article

References (13)

1. Burnett A, Wetzler M, Löwenberg B: Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487-494, 2011
2. Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. Blood 107:3481-3485, 2006
3. Hinman LM, Hamann PR, Wallace R, et al: Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics. Cancer Res 53:3336-3342, 1993 (Pubitemid 23223306)
4. Linenberger ML: CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19:176-182, 2005 (Pubitemid 40220577)
5. Larson RA, Sievers EL, Stadtmauer EA, et al: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33- positive acute myeloid leukemia in first recurrence. Cancer 104:1442-1452, 2005 (Pubitemid 41356159)
6. Amadori S, Suciu S, Willemze R, et al: Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: A phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 89:950-956, 2004 (Pubitemid 39049903)
7. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
8. Kalbfleisch JD, Prentice RL: The Survival Analysis of Failure Time Data (ed 2). Hoboken, NJ, Wiley Inter-Science, 2002
9. Rizzieri DA, O'Brien JA, Broadwater G, et al: Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer 115:2922-2929, 2009
10. van der Velden VH, te Marvelde JG, Hoogeveen PG, et al: Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97:3197-3204, 2001
11. Petersdorf S, Kopecky K, Stuart RK, et al: Preliminary results of Southwest Oncology Group study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 114:326-327, 2009 (abstr 790)
12. Castaigne S, Pautas C, TerréC, et al: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukemia (ALFA- 0701): A randomized, open-label, phase 3 study. Lancet 379:1508-1516, 2012
13. Burnett AK, Russell NH, Hills RK, et al: Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30:3924-3931, 2012